PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device

MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo AI, Inc., an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, today announced that Health Canada has formally acknowledged Spryng® with OsteoCushion® Technology as a veterinary medical device for use in Canada.

Spryng is a veterinarian-administered, intra-articular injectable device developed to support joint health and aid in the management of lameness and other joint-related afflictions in animals. This regulatory acknowledgement by Health Canada represents a key milestone in the Company’s global commercialization strategy and underscores the product’s recognition by a major international regulatory authority.

“Receiving acknowledgment from Health Canada that Spryng meets the criteria for a veterinary medical device is an important endorsement of our scientific and regulatory strategy,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “This acknowledgment reflects our continued commitment to expanding access to innovative, safe, and effective solutions that improve the health and mobility of companion animals and athletic equines. We look forward to advancing Spryng’s availability in Canada as part of our broader global growth plan.”

While Health Canada’s acknowledgement represents an important regulatory milestone, Spryng is not expected to be immediately available in Canada due to ongoing distribution infrastructure development, Canadian-specific packaging and labeling preparations, and other operational requirements. Subject to the completion of these items, the Company currently anticipates a potential commercial availability in Canada in the second calendar quarter of 2026.

Spryng with OsteoCushion Technology has garnered interest from veterinarians and animal health partners worldwide, and this latest regulatory milestone further supports PetVivo’s efforts to bring transformative joint support solutions to the global veterinary market.

Spryng is commercially available in the United States and through select distribution partners internationally.

For more information about Spryng and PrecisePRP, please contact info1@petvivo.com or visit petvivo.com, petvivoanimalhealth.com and sprynghealth.com.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking commercial Statements

The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.